Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6277050 | Neuroscience | 2010 | 10 Pages |
Abstract
A novel pyridine derivative, 8-{4-[(6-methoxy-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine-3-ylmethyl)-amino]-butyl}-8-aza-spiro[4.5]decane-7,9-dione hydrochloride, termed JB-788, was designed to selectively target 5-HT1A receptors. In the present study, the pharmacological profile of JB-788 was characterized in vitro using radioligands binding tests and in vivo using neurochemical and behavioural experiments. JB-788 bound tightly to human 5-HT1A receptor expressed in human embryonic kidney 293 (HEK-293) cells with a Ki value of 0.8 nM. Its binding affinity is in the same range as that observed for the (±)8-OH-DPAT, a reference 5HT1A agonist compound. Notably, JB-788 only bound weakly to 5-HT1B or 5-HT2A receptors and moreover the drug displayed only weak or indetectable binding to muscarinic, α2, β1 and β2 adrenergic receptors, or dopaminergic D1 receptors. JB-788 was found to display substantial binding affinity for dopaminergic D2 receptors and, to a lesser extend to α1 adrenoreceptors. JB-788 dose-dependently decreased forskolin-induced cAMP accumulation in HEK cells expressing human 5-HT1A, thus acting as a potent 5-HT1A receptor agonist (Emax. 75%, EC50 3.5 nM). JB-788 did not exhibit any D2 receptor agonism but progressively inhibited the effects of quinpirole, a D2 receptor agonist, in the cAMP accumulation test with a Ki value of 250 nM. JB-788 induced a weak change in cAMP levels in mouse brain but, like some antipsychotics, transiently increased glycogen contents in various brain regions. Behavioral effects were investigated in mice using the elevated plus-maze. JB-788 was found to increase the time duration spent by animals in anxiogenic situations. Locomotor hyperactivity induced by methamphetamine in mouse, a model of antipsychotic activity, was dose-dependently inhibited by JB-788. Altogether, these results suggest that JB-788 displays pharmacological properties, which could be of interest in the area of anxiolytic and antipsychotic drugs.
Keywords
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
M. Picard, S. Morisset, J.F. Cloix, J.C. Bizot, M. Guerin, V. Beneteau, G. Guillaumet, T.K. Hevor,